These findings implicated CCL2 as the key tumor cell-derived agonist of CCR2 in the A3250 model and strongly suggested an important role for CCL2 in monocyte and macrophage recruitment to both A3250 primary and metastatic sites. Here, CCL2 is linked to neoplasm.